Table 4.
Risk factors for CMV, fungal and bacterial infection in our study cohort of 347 patients.
| Risk Factors (Univariate Analysis) | Fungal Infections | Bacterial Infections | CMV Symptomatic Infection or End-Organ Disease | |||
|---|---|---|---|---|---|---|
| Yes | p | Yes | p | Yes | p | |
| Diagnosis | 0.035 | 0.005 | NS | |||
| Lymphoma (#188) | 10 (5.3%) | 80 (42.5%) | 30 (16%) | |||
| Myeloma (#159) | 2 (1.2%) | 45 (28%) | 24 (15%) | |||
| Disease status at transplant | NS | 0.04 | 0.039 | |||
| CR + PR (#328) | 11 (3.3%) | 116 (35.4%) | 47 (14.3%) | |||
| Refractory disease (#19) | 1 (5.3%) | 9 (47.4%) | 7 (36.8%) | |||
| Neutropenia duration (*) | NS | <0.001 | 0.004 | |||
| <7 days (#123) | 4 (3.2%) | 25 (20.3%) | 10 (8.1%) | |||
| ≥7 days (#219) | 8 (3.6%) | 100 (45.6%) | 44 (20%) | |||
| Previous treatment lines | 0.009 | NS | NS | |||
| ≤2 (#304) | 7 (2.3%) | 113 (37.2%) | 48 (15.8%) | |||
| 3 or more (#43) | 5 (11.6%) | 12 (27.9%) | 6 (13.9%) | |||
| Age | 0.001 | NS | NS | |||
| <60 years (#230) | 3 (1.8%) | 84 (36.5%) | 31 (13.5%) | |||
| ≥60 years (#117) | 9 (7.7%) | 41 (35%) | 23 (19.6%) | |||
| Transplant period | NS | NS | NS | |||
| 2004–2011 (#112) | 2 (1.8%) | 44 (39.3%) | 18 (16.1%) | |||
| 2012–2018 (#235) | 10 (4.2%) | 81 (34.5%) | 36 (15.3%) | |||
CR: complete remission; PR: complete remission; CMV: cytomegalovirus; NS: not statistically significant. (*) data not available in 5 cases (death in aplasia).